We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Level up your trading with our powerful tools and real-time insights all in one place.
The current FARN market cap is 204.01M. The company's latest EPS is EUR -0.2958 and P/E is -6.59.
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| EUR (€) | EUR (€) | EUR (€) | EUR (€) | EUR (€) | |
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -13.1M | -16.65M | -21.11M | -27.43M | -28.57M |
| Net Income | -13.26M | -16.95M | -21.19M | -28.73M | -30.94M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| EUR (€) | EUR (€) | EUR (€) | EUR (€) | EUR (€) | |
| Total Assets | 10.21M | 8.37M | 13.18M | 11.27M | 10.22M |
| Total Liabilities | 8.6M | 10.22M | 10.26M | 22.75M | 25.38M |
| Total Equity | 1.61M | -1.85M | 2.92M | -11.48M | -15.16M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| EUR (€) | EUR (€) | EUR (€) | EUR (€) | EUR (€) | |
| Operating | -11.52M | -17.48M | -22.22M | -22.99M | -23.81M |
| Investing | -100k | -142k | -473k | -385k | -123k |
| Financing | 14.61M | 14.79M | 25.59M | 23.48M | 23.98M |
| Market Cap | 204.01M |
| Price to Earnings Ratio | -6.59 |
| Price to Sales Ratio | 0 |
| Price to Cash Ratio | 29.68 |
| Price to Book Ratio | -13.46 |
| Dividend Yield | - |
| Shares Outstanding | 104.62M |
| Average Volume (1 week) | 12.09k |
| Average Volume (1 Month) | 10.32k |
| 52 Week Change | -32.76% |
| 52 Week High | 306.00 |
| 52 Week Low | 89.00 |
| Spread (Intraday) | 10 (5%) |
| Company Name | Faron Pharmaceuticals Oy |
| Address |
joukahaisenkatu 6, intelligate turku FIN-20520 |
| Website | https://www.faronpharmaceuticals.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
